1 / 8

Nabil-Lally-Represent-Quotient-Sciences-at-ASCPT-2025

As the Senior Director of Business Development at Quotient Sciences, Nabil Lally plays a vital role in aligning scientific innovation with sponsor needs. At ASCPT 2025, his presence symbolized the company's proactive engagement with the clinical pharmacology community.<br>https://www.linkedin.com/posts/quotient-sciences_ascpt-quotientsciences-clinicalpharmacology-activity-7331665313580658691-RJz8/

Nabil38
Download Presentation

Nabil-Lally-Represent-Quotient-Sciences-at-ASCPT-2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nabil Lally Represent Quotient Sciences at ASCPT 2025 Transforming drug development through integrated science and innovation.

  2. ASCPT 2025: A Hub for Translational Medicine The American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2025 Annual Meeting in Washington, D.C., was a landmark event for translational medicine. It united global researchers, clinicians, and leaders, fostering scientific exchange and collaboration on the future of drug development.

  3. Quotient Sciences' Key Representatives Nabil Lally Dr. Andreas Reichl Senior Director, Business Development Senior Drug Development Consultant

  4. Our Commitment to Innovation Integrated Platform Science-Led Approach Translational Focus Advancing drug development with a seamless, end-to-end approach. Leveraging deep scientific expertise for better clinical outcomes. Bridging the gap from discovery to clinical application.

  5. Understanding Translational Pharmaceutics Translational Pharmaceutics integrates drug substance, drug product, and clinical testing all within a single organization. This unique approach allows for real-time decision-making and rapid progression of drug candidates, reducing timelines and costs.

  6. Benefits of an Integrated Approach Accelerated Timelines Cost Efficiency Enhanced Decision-Making Streamlined processes reduce the time from candidate selection to clinical data. Minimized delays and rework lead to significant cost savings in drug development. Real-time data access enables agile and informed strategic decisions.

  7. Our Consultative Clinical Pharmacology Quotient Sciences provides expert guidance throughout the clinical pharmacology phase. Our consultants work closely with clients to design optimal study protocols, analyze data, and navigate regulatory pathways, ensuring robust and compliant drug development.

  8. Next Steps: Partner with Quotient Sciences • Explore our Translational Pharmaceutics platform for your next drug candidate. • Connect with Nabil Lally and Dr. Andreas Reichl for in-depth consultations. • Visit our website to learn more about our integrated drug development solutions. Contact us today to revolutionize your drug development journey!

More Related